Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the Commercial Health Insurance Innovative Drug Catalog (2025), which will be implemented nationwide starting January 1, 2026 [1] Group 1: National Basic Medical Insurance Drug Catalog - The updated National Medical Insurance Drug Catalog adds 114 new drugs, including 50 first-class innovative drugs, while removing 29 drugs that are either not clinically available or can be better replaced by other medications [1] - After the adjustments, the total number of drugs in the catalog increases to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, significantly enhancing coverage for key areas such as oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications [1] Group 2: Commercial Health Insurance Innovative Drug Catalog - The inaugural Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, which complements the basic medical insurance, laying a foundation for the differentiated development of commercial insurance and basic medical insurance, and establishing a multi-tiered medical security system [1]

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs for 2025, effective from January 1, 2026 [1] Summary by Categories National Medical Insurance Drug Catalog - The updated catalog includes 114 new drugs, of which 50 are first-class innovative drugs [1] - A total of 29 drugs that are either not clinically available or can be better replaced by other medications have been removed [1] - The total number of drugs in the catalog has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [1] - There is a significant enhancement in coverage for key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1] Commercial Health Insurance Innovative Drug Catalog - The inaugural commercial health insurance innovative drug catalog includes 19 drugs, which complements the basic medical insurance [1] - This initiative aims to promote the differentiated development of commercial insurance and basic medical insurance, laying the groundwork for a multi-tiered medical security system [1]

新版药品目录将于2026年1月1日在全国范围内正式实施。国家医保局有关负责人表示，随着更多新药进 入目录，临床用药水平将得到稳步提升，同时有效提振医药行业加大研发创新的信心。下一步，国家医 保局、人力资源和社会保障部将进一步细化政策、加强管理，切实做好目录落地，更好保障参保人合理 的临床用药需求，不断提升人民群众的获得感、幸福感、安全感。 新版药品目录是国家医保局成立以来的第八次调整，已形成常态化、规范化、科学化的调整机制。 备受关注的首版商保创新药目录共纳入19种药品，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈 谢病等罕见病治疗药品，还有社会关注度较高的阿尔茨海默病治疗药品，与基本医保形成较好的互补衔 接，也为进一步厘清基本医保保障边界，推动商业健康保险与基本医保错位发展，建立多层次医疗保障 体系奠定基础。 本报北京12月7日电(记者孙秀艳)国家医保局、人力资源和社会保障部近期会同有关部门组织开展了 2025年国家基本医疗保险、生育保险和工伤保险药品目录调整和商业健康保险创新药品目录制定工作， 现已顺利完成。7日，两部门公布了《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(以 下简称 ...

Group 1 - The "Commercial Health Insurance Innovative Drug Directory (2025)" is the first of its kind in China, focusing on high-innovation drugs with significant clinical value that exceed the basic medical insurance's "basic protection" scope [1] - A total of 121 drug generic names were reviewed for inclusion in the commercial health insurance innovative drug directory, with 19 drugs from 18 innovative pharmaceutical companies successfully included, resulting in an acceptance rate of approximately 15.7% [1] - The directory aims to complement the basic medical insurance directory, supporting the development of innovative drugs and enhancing the multi-tiered medical insurance system [1] Group 2 - The selected drugs reflect advancements in medical technology and address key areas such as Alzheimer's disease and rare diseases prevalent in children [2] - North Sea Kangcheng's drug "Gorain" is the first domestically developed enzyme replacement therapy for Gaucher disease, which has been approved for use in adolescents and adults [2] - Five domestic CAR-T products have been included in the directory, involving companies such as WuXi AppTec and Kintor Pharmaceutical [2] Group 3 - The inclusion of CAR-T products in the directory is expected to significantly reduce patient out-of-pocket expenses and improve accessibility and affordability [3] - The industry anticipates a positive impact from the inclusion of CAR-T products, enhancing commercial accessibility and supporting the growth of the pharmaceutical health sector [3] - Companies are considering expanding their supply chains and collaborating with domestic suppliers to support the rapid scaling of CAR-T products [3]

Core Viewpoint - The article discusses the implementation of a "dual directory" for medical insurance in China, which includes a basic medical insurance directory and a commercial health insurance innovative drug directory, effective from January 1, 2026. This aims to enhance access to high-value innovative drugs that are not covered by basic insurance [2][5][10]. Group 1: Innovative Drug Directory - The first version of the commercial health insurance innovative drug directory includes 19 drugs, comprising 14 cancer treatment drugs and 2 Alzheimer's drugs [6][10]. - The inclusion of drugs in the commercial health insurance innovative drug directory requires price negotiations, with expected price reductions of 20%-40% [16][21]. - The directory aims to address the needs for high-value drugs that exceed the basic medical insurance coverage, thereby alleviating the financial burden on patients [5][13]. Group 2: Impact on Patients and Insurance - The commercial health insurance innovative drug directory is not subject to DRG/DIP payment restrictions, facilitating better access to these drugs [22][24]. - The integration of "medical insurance + commercial insurance" is expected to streamline the settlement process for patients, reducing their financial and time burdens [25][28]. - The article highlights three benefits for consumers: access to drugs without DRG/DIP limitations, potential for one-stop settlement, and the establishment of a consistent drug list across insurance companies [22][25][26].

Core Insights - The article discusses the recent adjustments to the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, highlighting the government's commitment to supporting innovative and differentiated drug development through strategic purchasing [1][2]. Group 1: Drug Catalog Adjustments - On December 7, the National Healthcare Security Administration (NHSA) released the updated drug catalog for 2025, which includes 114 new drugs, of which 50 are classified as Class 1 innovative drugs [2]. - The overall success rate of drug negotiations for the insurance catalog has improved to 88% in 2025, up from 76% in 2024, indicating a more favorable environment for drug inclusion [2]. - The total number of drugs in the catalog has increased to 3,253, with significant enhancements in coverage for critical areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [2]. Group 2: Financial Implications - Over the "14th Five-Year Plan" period, the cumulative expenditure of the medical insurance fund has exceeded 13 trillion yuan, benefiting nearly 20 billion patient visits [1]. - The NHSA has included 835 new drugs in the insurance payment scope over the past seven years, with 149 of these being innovative drugs, and approximately 80% of innovative drugs are included in the catalog within two years of their market launch [1]. - The NHSA's negotiations have resulted in over 4.6 trillion yuan in expenditures for negotiated drugs, driving sales exceeding 6 trillion yuan [1]. Group 3: Commercial Health Insurance Innovations - The first version of the commercial health insurance innovative drug catalog was introduced, including 19 drugs that are highly innovative and provide significant clinical value, such as CAR-T therapies and treatments for rare diseases [3]. - This new catalog aims to complement the basic medical insurance, clarifying the boundaries of basic insurance coverage and promoting the development of a multi-tiered medical security system [3].

Core Points - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) along with the first Commercial Health Insurance Innovative Drug Catalog (2025), focusing on high-innovation and clinically valuable drugs [1] - A total of 24 drugs participated in the price negotiation, with 19 successfully included, achieving a success rate of approximately 79% [1] - The included innovative drugs feature 5 CAR-T cell therapies, 6 rare disease drugs, and the only immune oncology drug in the commercial health insurance catalog [1] Group 1: CAR-T Cell Therapies - Five CAR-T cell therapies have been included in the commercial health insurance innovative drug catalog, which had previously attempted to enter the national insurance catalog four times without success [2][3] - The therapies included are from various companies, with the first approved CAR-T therapy being the Axicabtagene Ciloleucel injection from Fosun Kite [3] - Despite high treatment costs, the inclusion in the commercial catalog is expected to improve patient access and reduce financial burdens [3] Group 2: Oncology Drugs - The commercial health insurance innovative drug catalog includes a significant number of oncology drugs, with 14 drugs in total, accounting for nearly 74% of the catalog [5] - Notably, the CTLA-4 inhibitor Ipilimumab injection, the only immune oncology drug included, is expected to enhance treatment accessibility for liver cancer patients [6] Group 3: Rare Disease Drugs - The catalog also includes 6 innovative drugs for rare diseases, such as the drugs for neuroblastoma and phenylketonuria [8][10] - These drugs are aimed at addressing urgent patient needs and are part of a broader strategy to enhance treatment options for rare diseases [8] Group 4: Policy Implications - The establishment of the commercial health insurance innovative drug catalog is a significant step towards improving the multi-tiered medical insurance system in China [9] - The government encourages commercial health insurance providers to incorporate these drugs into their coverage, promoting a more comprehensive healthcare solution for patients [9]

仅仅依靠基本医保难以承担支持创新的重任，医保要有边界，要给市场"留白"。 按照30%的药占比计算，我国每年约3万亿元的医疗保险基金支出中，有超过1万亿元用于药品支出，这 是我国医保基金支持医药创新的"基本盘"。 在12月7日的2025创新药高质量发展大会上，国家医保局局长章轲表示，医保购买创新医药产品，就是 为群众买健康，为健康买未来。医保基金作为中国医药领域最大的购买方，"十四五"期间累计支出约13 万亿元，并保持了年均10%以上的较高增速，为创新提供了稳定的资金来源，注入了持久的发展动力。 国家医保局在这次会议上同步发表了医保商保的"双目录"。2025年国家医保药品目录新增114种药品， 有50种是一类创新药，总体成功率88%。同时，19种药品纳入首版商保创新药目录。 国家医保局表示，商保创新药目录的推出与基本医保形成较好的互补衔接，也为进一步厘清基本医保保 障边界、推动商业健康保险与基本医保错位发展、建立多层次医疗保障体系奠定了基础。 市场上有种声音说，国家医保局推出商保创新药目录可能是基本医保不想为创新药付费了。对此，国家 医保局医药管理司司长黄心宇明确表示，国家医保局从来没有这种打算，而且在可见的未 ...

Core Insights - The first national commercial insurance innovative drug directory for 2025 has been released, including 19 high-value innovative drugs covering key treatment areas such as oncology, rare diseases, and neurodegenerative diseases [1][3][4] - Shenzhen's "Shenzhen Huiminbao" has proactively included all 19 innovative drugs in its coverage for 2025, significantly reducing out-of-pocket expenses for insured residents when using these drugs [1][2][3] Summary by Sections National Drug Directory - The newly published commercial insurance innovative drug directory serves as a supplement to basic medical insurance, focusing on drugs with high innovation, significant clinical value, and substantial patient benefits that exceed the coverage of basic medical insurance [1][4] - Included drugs feature CAR-T therapies for cancer treatment, medications for rare diseases like Gaucher disease, and drugs for Alzheimer's disease, which has garnered significant public attention [1][4] Shenzhen Huiminbao - "Shenzhen Huiminbao" has achieved full coverage of the 19 innovative drugs, providing a crucial supplement to the existing medical insurance framework in Shenzhen [1][4] - The insurance plan supports a "one-stop settlement" service, alleviating the financial burden on insured individuals when seeking medical treatment [2][4] - The program has been operational for three years, maintaining a public welfare characteristic with no restrictions on age, occupation, or health status, allowing for an annual premium of 88 yuan for coverage exceeding 4 million yuan [5] - As of 2025, the number of insured individuals has surpassed 6.15 million, with a total of over 18 million insured instances in three years [5]

Core Viewpoint - The first national "Commercial Health Insurance Innovative Drug Directory" has been officially released, including 19 drugs that cover treatments for tumors, rare diseases, chronic diseases, and Alzheimer's disease [1][20]. Group 1: Overview of the Drug Directory - The directory includes 19 drugs, with a focus on those with high clinical value and innovation that exceed basic medical insurance coverage [1][20]. - The National Medical Insurance Administration received 141 submissions for the directory, with 121 passing initial reviews, ultimately including 19 drugs from 18 innovative pharmaceutical companies [4][23]. Group 2: Inclusion of CAR-T Therapies - Five CAR-T cell therapies from companies like Fosun Kite, Huyuan Bio, and WuXi AppTec have been included, which are among the most advanced cancer treatments globally [5][24]. - The inclusion of these therapies, previously priced over one million yuan, is expected to significantly alleviate the financial burden on patients [5][24]. Group 3: Impact on Commercial Health Insurance - The directory aims to enhance the integration of commercial health insurance with basic medical insurance, contributing to a multi-tiered medical security system [3][22]. - The commercial health insurance sector is projected to see a premium income of 977.3 billion yuan in 2024, with expectations to exceed one trillion yuan for the first time [14][16]. Group 4: Challenges and Opportunities - Despite the potential benefits, commercial health insurance faces challenges in pricing and risk management, particularly with newly listed drugs lacking extensive data [17][18]. - The directory's release is seen as a critical step in China's healthcare security system, but effective integration with commercial health insurance remains a significant challenge [19][20].